Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?.
10.3904/kjim.2014.29.5.577
- Author:
Seung Ki KWOK
1
Author Information
1. Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. seungki73@catholic.ac.kr
- Publication Type:Editorial ; Comment
- MeSH:
Antirheumatic Agents/*therapeutic use;
Arthritis, Rheumatoid/*drug therapy;
Humans;
Piperidines/*therapeutic use;
Pyrimidines/*therapeutic use;
Pyrroles/*therapeutic use
- From:The Korean Journal of Internal Medicine
2014;29(5):577-579
- CountryRepublic of Korea
- Language:English
-
Abstract:
No abstract available.
